Cellectis
CLLS
44 hedge funds and large institutions have $176M invested in Cellectis in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 48 → 44 (-4)
19% less capital invested
Capital invested by funds: $219M → $176M (-$42.4M)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
THSP
Taube Hodson Stonex Partners
London,
United Kingdom
|
+$4.1M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.48M |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$561K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$397K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$323K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.31M |
| 2 |
Millennium Management
New York
|
-$3.85M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.9M |
| 4 |
Goldman Sachs
New York
|
-$1.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
51
Virtu KCG Holdings
New York
| – | -$475K | -15,310 | Closed |
|
|
QOP
52
Quinn Opportunity Partners
Charlottesville,
Virginia
| – | -$261K | -8,400 | Closed |
|
53
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$124K | -4,000 | Closed |
|
|
PCM
54
Prelude Capital Management
New York
| – | -$31K | -1,000 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$2.05K | -85 | -85% |
|
CLLS Hedge Fund Activity: Q1 2016 in Review
44 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2016, worth a combined $176M — down 19% from $219M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CLLS and 7 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was Taube Hodson Stonex Partners, opening a new position worth an estimated $4.1M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $9.31M sold.
- 44 institutional investors held Cellectis (CLLS) as of Q1 2016, down from 48 in Q4 2015.
- Funds reported $176M of Cellectis stock for Q1 2016, down 19% quarter-over-quarter.
- 7 funds opened new Cellectis positions in Q1 2016 and 11 closed out, a net change of -4 holders.
- The largest Cellectis buyer in Q1 2016 was Taube Hodson Stonex Partners, an estimated $4.1M added.
- The largest Cellectis seller in Q1 2016 was JP Morgan Chase, an estimated $9.31M sold.
Based on aggregated 13F filings for Q1 2016.